Please login to the form below

Not currently logged in
Email:
Password:

postmenopausal osteoporosis

This page shows the latest postmenopausal osteoporosis news and features for those working in and with pharma, biotech and healthcare.

Amgen's Kyprolis scarred by head-to-head duel with Velcade

Amgen's Kyprolis scarred by head-to-head duel with Velcade

Romosozumab filed. There was some better news for Amgen and partner UCB this week when the FDA started its review of romosozumab, their drug candidate for the treatment of osteoporosis in ... postmenopausal women at increased risk of fracture.

Latest news

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    The company prematurely halted a phase III trial of the drug in 2012 after seeing a clear benefit on fractures rates in postmenopausal women with osteoporosis, although it did note at ... fractures in postmenopausal women with osteoporosis compared to

  • Amgen buys back product rights from GSK Amgen buys back product rights from GSK

    The US biopharma giant is reacquiring rights to denosumab - sold as Prolia for osteoporosis and Xgeva for bone metastases from solid tumours - and colorectal cancer therapy Vectibix (panitumumab). ... Meanwhile, Prolia received a boost recently after it

  • Merck & Co plays catch-up with osteoporosis data for odanacatib Merck & Co plays catch-up with osteoporosis data for odanacatib

    Merck &Co has revealed positive results from a phase III fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. ... The study enrolled 16, 713 women aged 65 years of age or older, diagnosed with osteoporosis, who have been

  • Onyx rejects $10bn takeover bid from Amgen Onyx rejects $10bn takeover bid from Amgen

    postmenopausal osteoporosis) while Aranesp failed to show efficacy in a phase III heart failure trial.

  • EMA recommends heart risk restriction for Servier's Protelos EMA recommends heart risk restriction for Servier's Protelos

    EMA recommends heart risk restriction for Servier's Protelos. Use of osteoporosis drug likely to be further tightened up. ... Restricting its use for the treatment of severe osteoporosis in postmenopausal women at high risk for fracture and severe

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics